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Abstract  
Objective: We examined longitudinal associations between pre-diabetes and cardiovascular 
disease (CVD) (coronary heart disease (CHD) and stroke) in Europeans and South Asians. 
Research design and methods: UK cohort study of 1,336 Europeans and 1,139 South 
Asians, aged 40-69 years at baseline (1988-91). Assessment included blood pressure, blood 
tests, anthropometry and questionnaires. Pre-diabetes was determined by OGTT or HbA1c, 
using either International Expert Committee (IEC, HbA1c 6.0-6.5% (42-48 mmol/mol)) or 
American Diabetes Association (ADA, HbA1c 5.7-6.5% (39-48 mmol/mol)) cut-points. 
Incident CHD and stroke were established at 20 years from death certification, hospital 
admission, primary care record review and participant report.  
Results: Compared to normoglycaemic individuals, IEC-defined pre-diabetes was related to 
both CHD and CVD risk in Europeans but not South Asians (sub-hazards ratio[95% CI]: 
CHD;1.68[1.19,2.37] vs. 0.99[0.74,1.33], ethnicity interaction p=0.008, CVD; 
1.49[1.08,2.07] vs. 1.03[0.79,1.36], ethnicity interaction p=0.04).  Conversely, IEC-defined 
pre-diabetes was associated with stroke risk in South Asians but not Europeans (1.75 
[1.04,2.93] vs. 0.85[0.45,1.64], ethnicity interaction p=0.11).  Risks were  adjusted for age, 
sex, smoking, total/HDL-cholesterol ratio, waist/hip ratio, systolic blood pressure and anti-
hypertensive use.  . Associations  were weaker for OGTT or ADA-defined pre-diabetes. 
Conversion from pre-diabetes to diabetes was greater in South Asians, but accounting for 
time to conversion did not account for these ethnic differences.    
Conclusions: Associations between pre-diabetes and CVD differed  by pre-diabetes 
diagnostic criterion, type of CVD and ethnicity, with associations being present for overall 
CVD in Europeans but not South Asians. Substantiation of these findings and investigation of 
potential explanations are required.
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In parallel with the global diabetes epidemic, population surveys indicate an escalating 
prevalence of non-diabetic hyperglycaemia (12-29%, depending on definition)(1); hereon in 
referred to as “pre-diabetes”. Historically, pre-diabetic states have been defined by either 
fasting (impaired fasting glycaemia [IFG]) or post-challenge (impaired glucose tolerance 
[IGT]) glycaemia(2), though  recently HbA1c-based definitions of pre-diabetes have been  
advocated(3, 4). Controversy exists regarding the role of pre-diabetes in cardiovascular 
disease (CVD) risk, particularly concerning whether pro-active identification and 
management are warranted(5). 
Large prospective studies indicate that glycaemia (by glucose or HbA1c) below the diabetic 
threshold is weakly related to CVD risk(6-8), and a recent Mendelian randomization study 
hinted at a limited causal role for dysglycaemia in coronary heart disease(9). However, 
studies examining the CVD consequences of pre-diabetes by specific diagnostic criteria are 
limited to European origin populations or focus on risk factors or mortality, rather than 
clinical disease(10-14). Host and migrant South Asian populations have a markedly greater 
prevalence of overt diabetes(15) and higher CVD rates than populations of European 
descent(16), yet associations between pre-diabetes and CVD have not been compared in these 
ethnic groups. Relatively more pre-diabetes is identified by HbA1c than IFG/IGT criteria in 
people of South Asian origin, whereas prevalence is similar by either criterion in European 
origin populations(17). Therefore, it has been suggested that the HbA1c definition of pre-
diabetes may be a less discerning indicator of CVD risk in South Asians(18). However, our 
previous work suggests that diabetes is more strongly related to CVD risk in South Asians 
than Europeans(16, 19); whether similar ethnic differences exist for pre-diabetes remains 
unstudied. 
Using data from a community-based cohort study, our objectives were: i) to examine 
longitudinal associations between pre-diabetes and CVD in UK Europeans and South Asians, 
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ii) to describe ethnic differences in these associations, and iii) to explore potential reasons for 
any ethnic differences.  
Research design and methods 
Study participants and design 
The Southall And Brent Revisited (SABRE) study is a community-based multi-ethnic cohort 
study of cardiometabolic disease; details are published elsewhere(20). Participants aged 40-
69 years at baseline (1988-1991, n=4857, 2346 European, 1710 South Asian and 801 African 
Caribbean) were randomly selected from primary care physician lists and workplaces in 
north-west London. South Asian participants were first-generation migrants originating from 
the Indian subcontinent, approximately half (52%) were of Punjabi Sikh origin. A male 
preponderance in the data exists as the baseline study was initially designed to examine 
cardiometabolic disease in men. Participants were followed for death, hospitalisation, and 
primary care consultations from baseline to 2011. All participants gave written informed 
consent. Approval for the baseline study was obtained from Ealing, Hounslow and 
Spelthorne, Parkside and University College London research ethics committees, and at 
follow-up from St. Mary’s Hospital Local Research Ethics Committee (reference: 
07/HO712/109). 
Baseline measurements 
Participants underwent blood tests, blood pressure and anthropometric measurement, and 
provided data on smoking, physical activity and occupation using previously validated 
questionnaires(21). Fasting lipids, glucose and HbA1c were measured as described(20, 22). 
HbA1c was measured (at baseline and follow-up) using an immunoassay on a clinically 
automated analyser (c311; Roche, Burgess Hill, UK), the high and low quality control 
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coefficients of variation were 2.9 and 3.3% respectively.  Those whose diabetes status was 
unknown underwent oral glucose tolerance testing (OGTT). We used three classification 
systems to define glycaemic status for participants without existing diabetes. Firstly, World 
Health Organisation (WHO) 1999 criteria were used to define pre-diabetes (either impaired 
fasting glycaemia [fasting glucose≥6.1 mmol/l and <7.0 mmol/l] or impaired glucose 
tolerance [2 hour oral glucose tolerance test plasma glucose≥7.8 mmol/l and <11.1 mmol/l]) 
and new diabetes (fasting glucose≥7.0mmol/l or 2 hour oral glucose tolerance test plasma 
glucose≥11.1 mmol/l)(2). Secondly, glycaemic categories according to the International 
Expert Committee (IEC) 2009 criteria(3) were based on the following HbA1c cut-points: pre-
diabetes; HbA 1c ≥6.0% (42 mmol/mol) but <6.5% (48 mmol/mol), new diabetes HbA1c 
≥6.5% (48 mmol/mol). We also studied glycaemia according to the American Diabetes 
Association (ADA) 2014 recommendations(4), which advocate HbA1c cut-points of ≥5.7% 
(39 mmol/mol) but <6.5% for pre-diabetes and ≥6.5% (as for IEC criteria) for new diabetes. 
Smoking status was dichotomised as ever/ never smoked. Weekly frequency of fruit and 
vegetable consumption was assessed by food frequency questionnaire. Questions on physical 
activity  provided a summary estimate of weekly energy expenditure in daily activities, 
walking and sport(23).  Height was measured barefoot with a stadiometer, weight with 
calibrated weighing scales, waist circumference halfway between the costal margin and the 
iliac crest and hip circumference at the greater trochanter. Seated resting brachial blood 
pressure was measured using a random zero sphygmomanometer (Hawksley, London, United 
Kingdom); the mean of two measurements was used in analyses.  
Follow-up measurements 
Between 2008 and 2011, survivors were invited for examination at St. Mary’s hospital, 
London. Incident coronary heart disease (CHD) was defined firstly from primary care record 
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review adjudicated by two clinicians – diagnosis was based on symptoms, cardiac enzymes, 
electrocardiography findings, exercise test findings and coronary revascularisation 
procedures, as per Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) criteria(24). 
Secondly, CHD was identified from Hospital Episode Statistics (HES) (ICD-9: 410-415, 
ICD-10: I200-I259) and data from the Office of Populations and Surveys classification of 
interventions and procedures (pertaining to coronary revascularisation interventions or 
rehabilitation for ischaemic heart disease, codes: K401-K469, K491-K504, K751-K759, 
U541). For stroke, primary care data were reviewed in a similar manner to CHD, with 
diagnoses made again according to ASCOT criteria, based on symptoms, duration of 
symptoms and magnetic resonance/ computer tomographic imaging(24). Stroke was also 
ascertained from participant report of physician-diagnosed stroke with duration of 
symptoms≥ 24 h and from Hospital Episode Statistics (ICD-9: 430-439, ICD-10: I600-I698). 
New cases of diabetes since baseline were identified from record review, questionnaire, clinic 
blood results, (using i) fasting and post OGTT load glucose results according to WHO 1999 
criteria, or ii) HbA1c ≥6.5% ), or death certificate data (ICD-9: 2500-2509, ICD-10: E100-
E149). 
Statistical analysis 
Baseline characteristics were compared by follow-up status and ethnicity. Logistic and linear 
regression methods determined age- and sex-adjusted differences. Using age- and sex-
adjusted Cox models, we compared rates of incident CHD, stroke and CVD (CHD + stroke) 
by ethnicity and studied numbers of events by glycaemic categories and ethnicity. Age- and 
sex-adjusted associations between pre-diabetes (defined in three ways, as above) or new/ 
known diabetes and CHD, stroke and CVD were examined in each ethnic group (model 1). 
We then further adjusted these models for potential a priori-specified confounders, 
comprising CVD risk factors (smoking, total/HDL-cholesterol ratio, waist/hip ratio, systolic 
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blood pressure (SBP) and anti-hypertensive treatment; model 2), and socio-demographic and 
lifestyle risk factors (smoking, manual occupation, physical activity and fruit and vegetable 
intake; model 3). Interactions between pre-diabetes or diabetes and ethnicity were sought in 
all models. Informative censoring may have occurred due to death from non-CVD causes; we 
addressed this by using competing risks regression (competing risk=death from non-CVD 
cause), based on Fine and Grey proportional subhazards methods(25). Additionally, we 
examined Nelson-Aalen cumulative hazard plots of CVD by glycaemic categories to check 
for violations of the proportional hazards assumption; none were found. 
Findings were further explored by comparing prevalence of CVD risk factors, medication use 
and resultant risk factor control by glycaemic status for each ethnic group at baseline and at 
follow-up, to establish whether disparities in these factors may have contributed to ethnic 
differences in pre-diabetes/ CVD associations. Since these comparisons suggested ethnic 
differences in lipid and blood pressure control by glycaemic status, we sought interactions 
between lipids and pre-diabetes in models of CHD and blood pressure and pre-diabetes in 
models of stroke. We compared rates of conversion from pre-diabetes to overt diabetes by 
pre-diabetes criterion and ethnicity, and sought to test whether greater conversion, and thus 
exposure to the hyperglycaemia of diabetes could account for ethnic differences observed in 
the association between pre-diabetes and CVD outcomes. 
Sensitivity analyses were conducted by: a) adjusting models for subsequent diabetes 
development as a time-varying covariate(26)), b)  excluding events within the first five years 
of follow-up and c) the inclusion of people with baseline CVD (adjusting for baseline CVD). 
Results 
We report findings from a subset of 1,336 Europeans and 1,139 South Asians without 
prevalent coronary heart disease (CHD) or stroke at baseline, with either a full set of baseline 
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HbA1c,  fasting and  post-load glucose measurements, or known diabetes, and with follow-up 
data for CHD and stroke (figure 1). African Caribbeans were excluded due to small numbers.  
There were no consistent differences between participants for whom we did and did not have 
the full set of blood samples.  
Overt diabetes was more prevalent, and cardiometabolic risk factors generally more adverse 
in South Asians than Europeans (table 1). South Asians had a higher prevalence of HbA1c-
defined pre-diabetes than Europeans, though prevalence was similar when impaired fasting 
glycaemia (IFG)/ impaired glucose tolerance (IGT) criteria were used. For both ethnic 
groups, the prevalence of pre-diabetes was over two-fold higher when defined by American 
Diabetes Association (ADA) HbA1c thresholds, as opposed to International Expert 
Committee (IEC) HbA1c thresholds or IFG/IGT.. 
Pre-diabetes was associated with an increased risk of CHD in Europeans, but not South 
Asians (table 2).  Associations were strongest for  IEC HbA1c -defined pre-diabetes. This 
association persisted  after adjustment for CVD risk factors and for socio-demographic and 
lifestyle factors (table 3). Conversely, in South Asians, no measure of pre-diabetes was 
associated with CHD risk. This ethnic difference in association between pre-diabetes and 
CHD was significant as an interaction (p=0.008 in the cardiovascular risk factor-adjusted 
model). Of note, diabetes was similarly related to CHD in each ethnic group regardless of 
diagnostic criteria. 
In contrast, no pre-diabetes measure was associated with stroke risk in Europeans, whereas 
for South Asians, all three measures were associated in age- and sex-adjusted models (table 
3). After adjustment for CVD risk factors, only the IEC HbA1c–defined pre-diabetes 
association retained significance, though associations for the other pre-diabetes measures 
remained of large magnitude. There was some evidence that this measure was more 
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associated with stroke risk in South Asians than Europeans (ethnicity interaction p=0.11 in 
the cardiovascular risk factor-adjusted model). Corresponding with ethnic differences in pre-
diabetes associations, overt diabetes also appeared to be more strongly associated with stroke 
risk in South Asians than Europeans, though again this was not significant as an interaction 
(p=0.18). 
Findings for CVD reflected those for CHD, with strong associations for pre-diabetes 
observed in Europeans but not South Asians, particularly for the IEC HbA1c criterion (p=0.04 
for ethnicity by pre-diabetes interaction). 
An important potential explanation for the ethnic differences observed in the association 
between pre-diabetes and CVD outcomes is control of key CVD risk factors.  At follow-up, a 
lower percentage of Europeans than South Asians with baseline pre-diabetes on lipid-
lowering medication had a total cholesterol<5.0 mmol/l (55% vs. 92%, p=0.004 for IEC-
defined pre-diabetes) or an LDL-cholesterol of <3.0 mmol/l (66% vs. 91%, p=0.03). Rates of 
lipid-lowering medication use were generally higher in South Asians than Europeans with 
baseline pre-diabetes (75% vs. 58%, 68% vs. 73%, 69% vs. 57% for IFG/IGT, IEC- and 
ADA-defined pre-diabetes respectively) (table 2, supplementary material). Adjusting for 
baseline lipids alone did not explain ethnic differences and there were no interactions 
between pre-diabetes and lipid measures on these outcomes.  
Baseline diastolic, but not systolic pressure, was higher in South Asians than Europeans.  But 
in addition, blood pressure control (defined as <140/90 mmHg for those on anti-
hypertensives) was generally worse in South Asians than Europeans with pre-diabetes, both 
at baseline and at follow-up (tables 1 and 2, supplementary material). Further, both mean 
diastolic and systolic pressures were higher in South Asians than Europeans in those on 
treatment.  No other baseline CVD risk factor appeared to be consistently worse in the pre-
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diabetic state in one ethnicity than the other (table 1, supplementary material). Ethnic 
differences in associations between pre-diabetes and stroke remained when adjusted for 
baseline blood pressure and use of anti-hypertensive medication, and again there were no 
statistically significant pre-diabetes x blood pressure (systolic or diastolic) interactions in 
either ethnic group.  
For participants with pre-diabetes at baseline, rates of conversion to overt diabetes were 
higher in South Asians than Europeans - 68% vs. 40%, p<0.001, 52% vs. 30%, p=0.006 and 
44 vs. 23%, p<0.001 for IFG/IGT, IEC- and ADA-defined pre-diabetes respectively. 
Sensitivity analyses adjusting for diabetes development as a time-varying covariate, 
excluding events within the first five years of follow-up and including people with baseline 
CVD (and adjusting for it) did not alter the main results (data not shown).  
Conclusions  
We show marked ethnic differences in associations between pre-diabetes and CVD. Pre-
diabetes was related to both CHD and CVD risk in Europeans but not South Asians.Strongest 
associations were observed for IEC than for ADA and OGTT criteria.  In contrast, only South 
Asians demonstrated an association between pre-diabetes and stroke. Associations persisted 
on multivariate adjustment and on accounting for differential rates of incident diabetes 
diagnosis.  Ethnic differences in baseline and follow-up CVD risk factor control may account 
for our findings (lipids for CHD in Europeans and blood pressure for stroke in South Asians). 
The  greater prevalence of pre-diabetes when defined by HbA1c as opposed to glucose-based 
criteria in South Asians, not observed  in Europeans, correspond with previous findings(17). 
However, we do not corroborate suggestions that classifying a higher number of South 
Asians as having pre-diabetes when HbA1c criteria are used results in a less discriminative 
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indicator of CVD risk(18), since for CHD, pre-diabetes by any criterion appeared unrelated in 
South Asians, and for stroke, pre-diabetes by all criteria was associated.  
For Europeans,  modest associations between pre-diabetes  and CHD correspond with 
previous findings(6, 7).  Associations between pre-diabetes by IEC HbA1c  criteria and CHD 
were stronger than those for glucose,  reflecting either greater  reproducibility of HbA1c(27), 
or better capture of  fed-state glycaemic status which may more closely associate  with 
CHD(10)). There are no comparable prospective data for South Asians. The INTERHEART 
case-control study reported a greater risk of myocardial infarction in the highest vs. lowest 
quintile of HbA1c in Western Europeans but not South Asians(28), the latter corroborated by 
cross-sectional data(29). 
Elevated lipids are key determinants of CHD risk (30).  Total and LDL-cholesterol in those 
on lipid-lowering medication at follow-up were higher in Europeans than South Asians with 
pre-diabetes in SABRE, reflecting findings in people with diabetes(31)).  Poor lipid control in 
pre-diabetic Europeans may have contributed to excess CHD risks compared to 
normoglycaemic individuals (and conversely, better control in South Asians may account for 
the lack of excess CHD in pre-diabetes).  Conversion rates from pre-diabetes to overt 
diabetes were higher in South Asians than Europeans, occurring at an earlier age(26).  This 
may have resulted in more aggressive and long-standing lipid management. Another 
possibility is that South Asians respond better to lipid-lowering(32), though  this appears 
unlikely(33). 
No associations were found between pre-diabetes and stroke for Europeans, whereas strong 
associations were seen in South Asians for all three criteria. Previous studies of  Europeans 
report  weak associations between fasting glucose, post-load glucose,  HbA1c and stroke(6, 7).  
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Stroke numbers were modest in SABRE, and may reflect better blood pressure control than 
historical cohorts.  
However blood pressure control in those with pre-diabetes on anti-hypertensives was worse 
in South Asians than Europeans at both baseline and follow-up,  suggesting suboptimal 
management of this  key  stroke risk factor (34). This may account for the positive 
association between pre-diabetes and stroke in South Asians, again  related to  higher 
diabetes conversion rates , since blood pressure appears  harder to control in South Asians 
then Europeans with diabetes(35, 36).  
As well as indicating likely progression to overt diabetes, incorporation of pre-diabetes into 
CVD risk scoring systems(14), or its use as a treatment target per se has been proposed(3, 4). 
However, the amalgamation of CHD and stroke risk may result in undertreatment of stroke 
risk in South Asians. Furthermore, our findings indicate that pre-diabetes is linked to overall 
CVD risk in Europeans only, and only for HbA1c–defined pre-diabetes, questioning the 
adoption of pre-diabetes as a trigger for population-level primary prevention. 
Mechanistically, these findings suggest that glycaemia may be more related to microvascular 
(stroke) than macrovascular (CHD) disease in South Asians than Europeans. We have  
described greater levels of retinal rarefaction(37), poorer microvascular responses to 
ischaemia(38) and more adverse cerebral circulatory autoregulation(39), and others  report 
greater cerebral microvascular disease(40), in South Asians than Europeans, with evidence 
that the latter two findings were mediated by hyperglycaemia. Furthermore, we have shown 
that the South Asian excess of stroke is largely explained by diabetes, commensurate with the 
current study’s results regarding pre-diabetes(16). However, it is unclear why non-diabetic 
glycaemia is not so obviously related to CHD in South Asians(28, 29). 
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This study is novel in comparing associations between pre-diabetes and CVD in South Asians 
and Europeans. Strengths include the use of three different diagnostic criteria for pre-
diabetes. HbA1c was not available on all participants at baseline and, as with any cohort 
study, loss to follow-up may have introduced bias. However, 88% of Europeans and 90% of 
South Asians were followed-up, and analyses comparing a) those with and without a full set 
of baseline bloods, and b) responders and non-responders did not detect bias.  Bias may have 
arisen from exposure misclassification, especially given the high variability of glucose 
measurements(27), though this is less likely for HbA1c. Whilst the study was well-powered 
for CHD and CVD analyses, the relatively small number of strokes made interpretation of 
associations more difficult, though internal validity was demonstrated, since associations 
between all pre-diabetes measures and stroke were similar.  Confounders such as use of and 
response to anti-hypertensive and lipid-lowering medication will have varied over time.  We 
attempted to address this by examination of follow-up clinic data. Finally, the South Asians 
in our study were of Indian origin, and may not necessarily apply to other South Asian sub-
groups. 
In summary, we show relations between pre-diabetes and CVD outcomes varied by pre-
diabetes diagnostic criterion, type of CVD and ethnicity. Despite calls for pre-diabetes to be 
pro-actively identified and treated(3, 4), we found that only pre-diabetes by IEC criteria 
(HbA1c 6.0-6.5% [42-48 mmol/mol]) in Europeans was linked with overall CVD risk. For 
South Asians, who experience greater pre-diabetes, greater rates of conversion to diabetes, 
and greater risks of CVD than Europeans, pre-diabetes was only clearly associated with 
stroke. These results need substantiating, with further exploration of contributory 
mechanisms and evaluation of screening and interventions in pre-diabetes, especially in 
South Asian groups. 
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Europeans South Asians p* 
N 1,336 1,139 - 
Age, years 53(47-59) 50(45-56) <0.001 
Women 186(14) 214(19) 0.001 
Ever smoked 930(70) 277(25) <0.001 
Manual occupation 809(61) 822(74) <0.001 
Fruit/ vegetables most days 933(70) 782(69) 0.9 
Physical activity, MJ/week 10(7-15) 9(4-12) <0.001 
BMI, kg/m2 26.1±4.0 26.1±3.6 0.7 
Waist/ hip ratio:    
Men 0.94±0.07 0.99±0.06 <0.001 
Women 0.79±0.09 0.87±0.09 <0.001 
Total cholesterol, mmol/l 6.1±1.14 5.9±1.05 <0.001 
HDL-cholesterol, mmol/l 1.3(1.1-1.5) 1.2(1.0-1.4) <0.001 
Total/ HDL-cholesterol ratio 4.7(3.8-5.8) 4.9(4.1-6.0) <0.001 
LDL-cholesterol, mmol/l 4.0±1.0 3.8±0.91 <0.001 
Triglycerides, mmol/l 1.4(1.0-2.1) 1.7(1.2-2.5) <0.001 
Systolic blood pressure, mmHg 123±17 125±18 <0.001 
Diastolic blood pressure, mmHg 77±11 80±11 <0.001 
Anti-hypertensive medication 113(8) 133(12) <0.001 
Glycaemic status: IFG/ IGT 
Normoglycaemia 1,125(84) 758(67) <0.001 
Pre-diabetes 128(10) 135(12) 0.07 
Diabetes† 83(6) 246(22) <0.001 
Glycaemic status: HbA1c  (IEC pre-diabetes criteria i.e. 6.0-6.5% [42-48 mmol/mol]) 
Normoglycaemia 1,170(88) 691(61) <0.001 
Pre-diabetes 92(7) 174(15) <0.001 
Diabetes† 74(6) 274(24) <0.001 
Glycaemic status: HbA1c  (ADA pre-diabetes criteria i.e. 5.7-6.5% [39-48 mmol/mol]) 
Normoglycaemia 903(68) 434(38) <0.001 
Pre-diabetes 359(27) 431(38) <0.001 
Diabetes† 74(6) 274(24) <0.001 
 
Table 1. Baseline characteristics of participants in the SABRE study, by ethnicity. Data 
are median (IQR), n (%) or mean±SD, *age- and sex-adjusted p for ethnic difference. 
†Includes pre-existing and newly-diagnosed diabetes by relevant criteria. IFG=impaired 
fasting glycaemia, IGT= impaired glucose tolerance, IEC= International Expert Committee, 
ADA=American Diabetes Association
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 Europeans South Asians 
Glycaemia 
measure 
Normo-
glycaemia 
Pre-diabetes 
New or known 
diabetes 
Normo-
glycaemia 
Pre-diabetes p⃰ 
New or 
known 
diabetes 
p† 
CHD 
IFG/ IGT 276/1,125 (25) 39/128 (30) 37/83 (45) 253/758 (33) 47/135 (35) 0.50 137/246 (56) 0.83 
HbA1c (IEC) 275/1,170 (24) 42/92 (46) 35/74 (47) 230/691 (33) 60/174 (34) 0.004 147/274 (54) 0.33 
HbA1c (ADA) 207/903 (23) 110/359 (31) 35/74 (47) 137/434 (32) 153/431 (35) 0.26 147/274(54) 0.38 
Stroke 
IFG/ IGT 85/1,125 (8) 12/128 (9) 11/83 (13) 53/758 (7) 17/135 (13) 0.15 46/246 (19) 0.12 
HbA1c (IEC) 90/1,170 (8) 8/92 (9) 10/74 (14) 47/691 (7) 20/174 (11) 0.13 49/274 (18) 0.22 
HbA1c (ADA) 68/903 (8) 30/359 (8) 10/74 (14) 25/434 (6) 42/431 (10) 0.10 49/274 (18) 0.13 
CVD 
IFG/ IGT 334/1,125 (30) 47/128 (37) 42/83 (51) 275/758 (36) 55/135 (41) 0.84 148/246 (60) 0.98 
HbA1c (IEC) 339/1,170 (29) 47/92 (51) 39/74 (53) 252/691 (36) 69/174 (40) 0.02 161/274 (59) 0.58 
HbA1c (ADA) 253/903 (28) 133/359 (37) 39/74 (53) 146/434 (34) 175/431 (41) 0.65 161/274 (59) 0.76 
 
Table 2. Distribution of incident cardiovascular disease by glycaemic status and ethnicity in the SABRE study. Data are number of events/ 
number of participants (%), ⃰p for age- and sex-adjusted ethnic difference in pre-diabetes vs. normoglycaemia, †p for age- and sex-adjusted 
ethnic difference in diabetes vs. normoglycaemia. CHD=coronary heart disease, CVD=cardiovascular disease, IFG=impaired fasting glycaemia, 
IGT=impaired glucose tolerance, IEC=international expert committee, ADA=American Diabetes Association.   
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 Europeans South Asians 
Glycaemia 
measure 
Model Normo-
glycaemia 
Pre-diabetes 
New or known 
diabetes 
Normo-
glycaemia 
Pre-diabetes p§ 
New or known diabetes 
p|| 
CHD 
IFG/ IGT 
1 1 1.19(0.85,1.69) 1.82(1.28,2.59) † 1 1.06(0.77,1.44) 0.50 1.86(1.50,2.30) ‡ 0.83 
2 1 1.03(0.72,1.47) 1.21(0.81,1.82) 1 0.97(0.72,1.32) 0.69 1.60(1.26,2.04) ‡ 0.66 
3 1 1.22(0.87,1.72) 1.80(1.26,2.57) † 1 1.06(0.77,1.45) 0.50 1.94(1.56,2.41) ‡ 0.84 
HbA1c 
(IEC) 
1 1 1.82(1.30,2.53) ‡ 2.01(1.39,2.90) ‡ 1 0.99(0.75,1.32) 0.004 1.73(1.40,2.14) ‡ 0.33 
2 1 1.68(1.19,2.38) † 1.35(0.89,2.03) 1 1.00(0.75,1.33) 0.008 1.44(1.13,1.83) † 0.67 
3 1 1.80(1.29,2.52) † 2.00(1.38,2.88) ‡ 1 0.99(0.74,1.32) 0.004 1.82(1.46,2.26)‡ 0.38 
HbA1c 
(ADA) 
1 1 1.22(0.97,1.54) 2.02(1.39,2.93) ‡ 1 1.07(0.85,1.34) 0.26 1.80(1.41,2.28) ‡ 0.38 
2 1 1.12(0.88,1.42) 1.31(0.86,1.99) 1 0.98(0.78,1.24) 0.25 1.42(1.09,1.87) † 0.66 
3 1 1.22(0.96,1.54) 1.98(1.36,2.89) ‡ 1 1.03(0.81,1.30) 0.21 1.84(1.44,2.34) ‡ 0.39 
Stroke 
IFG/ IGT 
1 1 0.92(0.51,1.68) 1.44(0.80,2.56) 1 1.75(1.03,2.98)* 0.15 2.65(1.84,3.93) ‡ 0.12 
2 1 0.83(0.45,1.56) 1.15(0.59,2.27) 1 1.51(0.86,2.64) 0.21 2.22(1.45,3.40) ‡ 0.09 
3 1 0.97(0.53,1.77) 1.57(0.88,2.82) 1 1.60(0.91,2.83) 0.27 2.64(1.79,3.89‡ 0.17 
HbA1c  
(IEC) 
1 1 0.91(0.47,1.75) 1.55(0.87,2.78) 1 1.80(1.09,2.97)* 0.13 2.59(1.69,3.72) ‡ 0.22 
2 1 0.85(0.44,1.64) 1.30(0.67,2.54) 1 1.73(1.03,2.90)* 0.11 2.19(1.37,3.25) ‡ 0.18 
3 1 0.92(0.48,1.76) 1.67(0.94,3.00) 1 1.66(1.00,2.79)* 0.20 2.50(1.67,3.73) ‡ 0.33 
HbA1c 
(ADA) 
1 1 0.97(0.65,1.45) 1.56(0.86,2.84) 1 1.69(1.05,2.72)* 0.10 2.93(1.83,4.69)v 0.13 
2 1 0.95(0.63,1.43) 1.31(0.66,2.59) 1 1.60(0.98,2.62) 0.12 2.51(1.52,4.14) ‡ 0.12 
3 1 0.95(0.64,1.42) 1.66(0.92,3.02) 1 1.64(0.99,2.70) 0.13 2.93(1.81,4.72) ‡ 0.20 
CVD 
IFG/ IGT 
1 1 1.17(0.86,1.60) 1.73(1.24,2.41) † 1 1.16(0.87,1.54) 0.84 1.83(1.49,2.25) ‡ 0.98 
2 1 1.03(0.74,1.42) 1.22(0.83,1.79) 1 1.05(0.79,1.40) 0.99 1.58(1.25,1.98) ‡ 0.51 
3 1 1.20(0.88,1.64) 1.75(1.25,2.45) † 1 1.12(0.83,1.51) 0.68 1.91(1.54,2.36) ‡ 0.94 
HbA1c  
(IEC) 
1 1 1.61(1.18,2.20) † 1.85(1.30,2.63) † 1 1.06(0.81,1.38) 0.02 1.77(1.44,2.17) ‡ 0.58 
2 1 1.49(1.08,2.07)* 1.31(0.88,1.95) 1 1.03(0.78,1.36) 0.04 1.45(1.15,1.83) † 0.97 
3 1 1.61(1.17,2.21) † 1.88(1.32,2.67) ‡ 1 1.03(0.78,1.36) 0.02 1.82(1.48,2.25) ‡ 0.59 
HbA1c 
(ADA) 
1 1 1.21(0.98,1.49) 1.88(1.31,2.68) † 1 1.19(0.96,1.48) 0.65 1.90(1.51,2.40) ‡ 0.76 
2 1 1.12(0.90,1.39) 1.30(0.87,1.94) 1 1.08(0.87,1.36) 0.63 1.51(1.17,1.96) † 0.87 
3 1 1.20(0.97,1.49) 1.89(1.32, 2.70) ‡ 1 1.12(0.90,1.41) 0.48 1.93(1.52,2.44) ‡ 0.69 
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Table 3. Competing risks regression models of incident cardiovascular disease by glycaemic status and ethnicity; the SABRE study. Data 
are sub hazards ratios (95% CI), *p<0.05, †p<0.01, ‡p<0.001. p for ethnic difference: §pre-diabetes vs. normoglycaemia, ||diabetes vs. 
normoglycaemia. Model 1: age, sex, model 2: age, sex, smoking, total/HDL-cholesterol, waist/hip ratio, SBP, anti-hypertensives, model 3: age, 
sex, smoking, manual occupation, physical activity and fruit and vegetable intake. CHD=coronary heart disease, CVD=cardiovascular disease, 
IFG=impaired fasting glycaemia, IGT=impaired glucose tolerance, IEC=international expert committee, ADA=American Diabetes Association.
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Figure legends 
 
Figure 1. Follow-up of the SABRE cohort 1988-2011. CVD=cardiovascular disease, 
FPG=fasting plasma glucose, PLG=post-load glucose. 
 
